Evofosfamide
- Generic Name
- Evofosfamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16Br2N5O4P
- CAS Number
- 918633-87-1
- Unique Ingredient Identifier
- 8A9RZ3HN8W
- Background
TH-302 is a novel cancer therapeutic specifically activated under the low oxygen or "hypoxic" conditions typical of solid tumor cancer cells. TH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide. TH-302 has been shown, in prec...
- Indication
Investigated for use/treatment in solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT03098160
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT01833546
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath